Large-Scale Generation of Natural Killer Lymphocytes for Clinical Application

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Hematotherapy & Stem Cell Research

• Publication date

  2002-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/15258160260194794PMID 12201953
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.

  2001cited by this paper
• Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset

  2001cited by this paper
• Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood.

  2001cited by this paper
• A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.

  2001cited by this paper
• Feasibility of the Adoptive Transfusion of Allogenic Human Leukocyte Antigen-Matched Natural Killer Cells in Patients With Renal Cell Carcinoma

  2000cited by this paper
• Human NK-cell receptors.

  2000cited by this paper
• Expression and kinetics of cytokines determined by intracellular staining using flow cytometry.

  1999cited by this paper
• Nerve growth factor: a neurotrophin with activity on cells of the immune system

  1999cited by this paper
• Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18.

  1999cited by this paper
• Participation of the CD94 receptor complex in costimulation of human natural killer cells.

  1998cited by this paper
• Evaluation of a flow cytometric method for simultaneous leukocyte phenotyping and quantification by fluorescent microspheres.

  1998cited by this paper
• EBV-NK cells interactions and lymphoproliferative disorders.

  1998cited by this paper
• Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals.

  1996cited by this paper
• High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.

  1996cited by this paper
• Production of Human Natural Killer Cells for Adoptive Immunotherapy Using a Computer-Controlled Stirred-Tank Bioreactor

  1996cited by this paper
• Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance.

  1995cited by this paper
• T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse

  1995cited by this paper
• Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2.

  1994cited by this paper
• Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy.

  1994cited by this paper
• Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12.

  1994cited by this paper
• Natural history of HLA expression during tumour development.

  1993cited by this paper
• A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.

  1992cited by this paper
• Human renal‐cell carcinoma cells are able to activate natural killer cells

  1992cited by this paper
• Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.

  1991cited by this paper
• Cell-mediated cytotoxicity: A highly sensitive and informative flow cytometric assay

  1989cited by this paper
• The effects of recombinant interleukin 2-activated natural killer cells on autologous peripheral blood hematopoietic progenitors

  1988cited by this paper
• Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.

  1987cited by this paper
• The influence of nerve growth factor on the in vitro proliferative response of rat spleen lymphocytes

  1987cited by this paper
• Human natural killer cells.

  1979cited by this paper
• Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3).

  1975cited by this paper

• A review and statistical analysis to identify and describe relationships between CQAs and CPPs of natural killer cell expansion processes.

  2024cites this paper
• A Critical Role of Culture Medium Selection in Maximizing the Purity and Expansion of Natural Killer Cells

  2024influential citation
• A clinically relevant large‐scale biomanufacturing workflow to produce natural killer cells and natural killer cell‐derived extracellular vesicles for cancer immunotherapy

  2023cites this paper
• Biology of NK Cells and NK Cells in Clinic

  2022cites this paper
• CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.

  2022cites this paper
• Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies

  2021influential citation
• NK cell-based cancer immunotherapy: from basic biology to clinical development

  2021cites this paper
• NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms

  2021cites this paper
• Antigen-independent killer cells prepared for adoptive immunotherapy: One source, divergent protocols, diverse nomenclature.

  2020cites this paper
• NK cells as adoptive cellular therapy for hematological malignancies: Advantages and hurdles.

  2020cites this paper
• Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma

  2020cites this paper
• Immunopathology and Immunotherapy of Hodgkin Lymphoma

  2020cites this paper
• Availability of NK cell expansion agent combined with recombinant IL‑2 and IL‑15 stimulation on the expansion and high‑purity of NK cells in patients with immune‑related pancytopenia in vitro.

  2019cites this paper
• Single‐Use Bioreactors for Manufacturing of Immune Cell Therapeutics

  2019cites this paper
• The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction

  2018cites this paper
• Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.

  2018cites this paper
• Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials

  2018cites this paper
• Impact of Antifungal Compounds on Viability and Anti-Aspergillus Activity of Human Natural Killer Cells

  2018cites this paper
• Ticagrelor inhibits platelet–tumor cell interactions and metastasis in human and murine breast cancer

  2018cites this paper
• Natural killer cells as a therapeutic tool for infectious diseases – current status and future perspectives

  2018cites this paper
• Prospect of Natural Killer Cells in Cancer Imunotherapy

  2018cites this paper
• Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours

  2017cites this paper
• NK Cell Subsets in Health and Disease: New Developments

  2017cites this paper
• Landscape of Manufacturing Process of ATMP Cell Therapy Products for Unmet Clinical Needs

  2017cites this paper
• Ex vivo expansion of CD3depleted cord blood-MNCs in the presence of bone marrow stromal cells; an appropriate strategy to provide functional NK cells applicable for cellular therapy.

  2017cites this paper
• Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation

  2017cites this paper
• Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients

  2017cites this paper
• Manufacturing Natural Killer Cells as Medicinal Products

  2016cites this paper
• The antileukemic potential of natural killer cells.

  2016cites this paper
• Isolation and (111)In-Oxine Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model.

  2016cites this paper
• Cryopreserved NK cells in the treatment of haematological malignancies: preclinical study

  2016cites this paper
• PHENOTYPE AND FUNCTIONALITY OF NATURAL KILLER CELLS EXPANDED FROM BREAST CANCER PATIENTS AND HEALTHY DONORS AGAINST BREAST CANCER CELL LINES

  2016cites this paper
• In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells

  2015influential citation
• “Adherent” versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy

  2015cites this paper
• Use of Natural Killer Cells for Acute Leukemia Patients

  2015cites this paper
• Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients

  2015cites this paper
• Influence of autologous dendritic cells on the in-vitro expansion and functions of peripheral blood NK cells

  2015cites this paper
• Ascorbic acid promotes proliferation of natural killer cell populations in culture systems applicable for natural killer cell therapy.

  2015cites this paper
• Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21.

  2015cites this paper
• Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer

  2015cites this paper
• Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy

  2015cites this paper
• Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies

  2015cites this paper
• Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

  2015cites this paper
• A New Ex Vivo Method for Effective Expansion and Activation of Human Natural Killer Cells for Anti-Tumor Immunotherapy

  2015cites this paper
• Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity

  2015influential citation
• Combined IL-15 and IL-12 drives the generation of CD34+-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer

  2015cites this paper
• A good manufacturing practice method to ex vivo expand natural killer cells for clinical use.

  2015cites this paper
• Culture bag systems for clinical applications of adult human neural crest-derived stem cells

  2014cites this paper
• Ex vivo activation and expansion of natural killer cells from patients with advanced cancer with feeder cells from healthy volunteers.

  2013cites this paper
• Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.

  2013cites this paper
• MiRNA-296-3p-ICAM-1 axis promotes metastasis of prostate cancer by possible enhancing survival of natural killer cell-resistant circulating tumour cells

  2013cites this paper
• Natural killer cells: a review of manufacturing and clinical utility

  2013cites this paper
• Bringing natural killer cells to the clinic: ex vivo manipulation.

  2013cites this paper
• Ex vivo expansion of natural killer cells using cryopreserved irradiated feeder cells.

  2013cites this paper
• Targeting the anti-inflammatory interplay promoting glioblastoma progression with combined natural killer cells and mab9.2.27 against NG2/CSPG4. A novel strategy to reveal glioblastoma to the immune system

  2013influential citation
• Expansion and genetic modification of human natural killer cells for adoptive immunotherapy of cancer

  2012cites this paper
• In vitro determination and functional maturation of natural killer cells from umbilical cord blood progenitor cells

  2012cites this paper
• Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells.

  2012cites this paper
• Use of allogeneic NK cells for cancer immunotherapy.

  2011cites this paper
• Natural killer cell engineering for cellular therapy of cancer.

  2011cites this paper
• Natural Killer Cells for Cancer Immunotherapy

  2011cites this paper
• Contribution à l'étude des mécanismes de l'alloréactivité des cellules Natural Killer humaines

  2010cites this paper
• Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.

  2010cites this paper
• Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.

  2010cites this paper
• IL-2−driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16− Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion

  2010cites this paper
• Retroviral gene transfer into primary human natural killer cells.

  2009cites this paper
• Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.

  2009influential citation
• Expansion and activation of natural killer cells for cancer immunotherapy.

  2009influential citation
• Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.

  2009cites this paper
• Natural killer cell‐based immunotherapy in cancer: current insights and future prospects

  2009cites this paper
• Immunobiology and Immunotherapy of Multiple Myeloma

  2008cites this paper
• Expanded donor natural killer cell and IL‐2, IL‐15 treatment efficacy in allogeneic hematopoietic stem cell transplantation

  2008cites this paper
• Potential therapeutic role of natural killer cells in cancer

  2007cites this paper
• Long-Term Preservation of Antibody-Dependent Cellular Cytotoxicity (ADCC) of Natural Killer Cells Amplified In Vitro From the Peripheral Blood of Breast Cancer Patients After Chemotherapy

  2006cites this paper
• Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.

  2006cites this paper
• A sealed and unbreached system for purification, stimulation, and expansion of cytomegalovirus‐specific human CD4 and CD8 T lymphocytes

  2006cites this paper
• Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice

  2005cites this paper
• Natural killer cell-based immunotherapeutic strategies.

  2005cites this paper
• Efficient gene transfer into primary human natural killer cells by retroviral transduction.

  2005cites this paper
• Monitoring of a new approach of immunotherapy with allogenic 111In-labelled NK cells in patients with renal cell carcinoma

  2004cites this paper
• Kinetics and Organ Distribution of Allogeneic Natural Killer Lymphocytes Transfused into Patients Suffering from Renal Cell Carcinoma

  2004cites this paper
• IL-15 alters expression and function of the chemokine receptor CX3CR1 in human NK cells.

  2004cites this paper
• Research Report Kinetics and Organ Distribution of Allogeneic Natural Killer Lymphocytes Transfused into Patients Suffering from Renal Cell Carcinoma

  2004cites this paper
• Ex vivo expansion of natural killer cells for clinical applications.

  2004cites this paper
• Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans.

  2003cites this paper